Sign In
CPSI Share                                                                      
​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​ ​​
Publication Type: Medication Safety Notice
Single or Multiple Incident: Multiple
Date: 6/1/2021 12:00:00 AM
Country: Australia

This safety notice is to raise awareness of two different insulin aspart formulations, namely Fiasp® and NovoRapid®. Fiasp® has a faster onset of action than NovoRapid® and a delay in food intake could result in hypoglycaemia. Hence administration times differ between the two insulins. Fiasp® and NovoRapid® are not interchangeable. The notice provides recommendations to prevent medication incidents with these two insulin aspart formulations.

Additional Details

Medication/Gas/Fluid:
insulin aspart (Fiasp®, NovoRapid®)
Medication/IV List:
insulin, subcutaneous and IV


New Insulin aspart formulations Fiasp and NovoRapid brand awareness and medication safety considerations